More than four million doses of the Covid-19 Abdala (CIGB-66) vaccine, the first such immunizer conceived and produced in Latin America, have been so far administrated to children and adolescents in Cuba and Nicaragua.
The first clinical studies of the application of Cuba’s first nasal vaccine candidate, named Mambisa, to patients convalescing from Covid-19 and as a booster are ongoing.
The magazine Chemical Biology of the UK Royal Society of Chemistry reviewed an article about the Cuban vaccine candidate Soberana01 and the advantages of this product against the SARS-CoV-2 coronavirus, media reported on Thursday.
Recent forecasts indicate that Cuba is going through the peak of the current outbreak of the Covid-19 pandemic and that there should be a rapid decrease in cases, experts informed President Miguel Díaz-Canel on Tuesday.